RNS Number : 2672L

Indivior PLC

11 January 2021

Indivior PLC - Directorate Change

Indivior PLC announces that Daniel Tassé has notified the Board of his intention to stand down as a Non-Executive Director of the Company in order to focus on his increasing business commitments. Mr Tassé will not stand for re-election at the Company's next Annual General Meeting and will stand down at the conclusion of that meeting.

Daniel Tassé has been a Non-Executive Director for over six years and is currently Senior Independent Director, Chair of the Audit Committee and a member of the Remuneration Committee. As announced in November 2020, a search is underway to identify an additional independent Non-Executive Director with recent and relevant financial experience and the search has been expanded to identify a further Non-Executive Director.

Graham Hetherington, Chair of the Board of Indivior PLC, commented:

'Daniel joined the Board in 2014 and was appointed Senior Independent Director in 2016. He has been a strong contributor since the Company's listing. His strategic and commercial experience and acumen have been invaluable, as was his strong leadership while stepping in as Interim Chair in June 2020 at a critical time for the Company. On behalf of the entire Board, I would like to extend our thanks to Daniel and wish him well.

This announcement is made pursuant to Listing Rule 9.6.11(2).

January 11, 2021

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

Investor Contact :

Jason Thompson, Indivior

Vice President, Investor Relations

+1 804-402-7123


Media Contacts :


Tulchan Communications

+44 207-353-4200



+1 804-594-0836

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 11, 2021 08:00 ET (13:00 GMT)

Indivior (LSE:INDV)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Indivior Charts.
Indivior (LSE:INDV)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Indivior Charts.